Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells

References

• Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces. 2015;7:6674–6682.
   PubMed Web of Science ®Google Scholar
• Nance E, Zhang C, Shih TY, et al. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano. 2014;8:10655–10664.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Pinheiro L, Brem H. Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther Deliv. 2015;6:353–369.
   PubMed Web of Science ®Google Scholar
• Ricci M, Blasi P, Giovagnoli S, et al. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem. 2006;13:1757–1775.
   PubMed Web of Science ®Google Scholar
• Shilo M, Motiei M, Hana P, et al. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale. 2014;6:2146–2152.
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2–14.
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2012;161:264–273.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127:97–109.
   PubMed Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454–477.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art . Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272.
   PubMed Web of Science ®Google Scholar
• Kamboj S, Bala S, Nair AB. Solid lipid nanoparticles: an effective lipid based technology for poorly water soluble drugs. Int J Pharm Sci Rev Res. 2010;5:78–90.
   Google Scholar
• Shi SJ, Zhong ZR, Liu J, et al. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 2012;29:97–109.
   PubMed Web of Science ®Google Scholar
• Jin SE, Kim CK, Kim YB. Cellular delivery of cationic lipid nanoparticle based SMAD3 antisense oligonucleotides for the inhibition of collagen production in keloid fibroblasts. Eur J Pharm Biopharm. 2012;82:19–26.
   PubMed Web of Science ®Google Scholar
• Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5:9977–9983.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Agrawal H, Tiwari S, et al. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting. Int J Pharm. 2011;421:189–201.
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Chen V, Paoletti P, et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6:363–373.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Bezares S, Tabernero JM, et al. Review of a promising new agent-pemetrexed disodium. Cancer. 2003;97:2056–2063.
   PubMed Web of Science ®Google Scholar
• Dai H, Chen Y, Elmquist F. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther. 2005;315:222–229.
   PubMed Web of Science ®Google Scholar
• Sorensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. 2011;7:919–928.
   PubMed Web of Science ®Google Scholar
• Griveau A, Bejaud J, Anthiya S, et al. Silencing of miR-21 by locked nucleic acid–lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. Int J Pharm. 2013;454:765–774.
   PubMed Web of Science ®Google Scholar
• Guz M, Rivero-M€uller A, Okon E, et al. MicroRNAs-role in lung cancer. Dis Markers. 2014;2014:218169.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin VP. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol. 2012;684:8–18.
   PubMed Web of Science ®Google Scholar
• Ren Y, Kang CS, Yuan X, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed. 2010;21:303–314.
   PubMed Web of Science ®Google Scholar
• Qian X, Ren Y, Shi Z, et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolamide and miR-21 inhibitor gene therapy. Mol Pharm. 2012;9:2636–2645.
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Mendonca LS, et al. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids. 2013;2:e100.
   PubMedGoogle Scholar
• Ananta JS, Paulmurugan R, Massoud TF. Nanoparticle-delivered antisense microRNA-21 enhances the effects of temozolomide on glioblastoma cells. Mol Pharm. 2015;12:4509–4517.
   PubMed Web of Science ®Google Scholar
• Bai H, Xu R, Cao Z, et al. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585:402–408.
   PubMed Web of Science ®Google Scholar
• Davis S, Lollo B, Freier S, et al. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34:2294–2304.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010;101:948–954.
   PubMed Web of Science ®Google Scholar
• Bishi DK, Mathapati S, Venugopal JR, et al. Patient-inspired ex vivo liver tissue engineering approach with autologous mesenchymal stem cells and hepatogenic serum. Adv Healthcare Mater. 2016;5:1058–1070.
   Web of Science ®Google Scholar
• McCloy RA, Rogers S, Caldon CE, et al. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle. 2014;13:1400–1412.
   PubMed Web of Science ®Google Scholar
• Xie S, Zhu L, Dong Z, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces. 2011;83:382–387.
   PubMed Web of Science ®Google Scholar
• Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129–137.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen HH. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm. 2009;365:206–213.
   PubMed Web of Science ®Google Scholar
• Asasutjarit R, Lorenzen SI, Sirivichayakul S, et al. Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHISHIV-Hugag transfection. Pharm Res. 2007;24:1098–1107.
   PubMed Web of Science ®Google Scholar
• Celia C, Cosco D, Paolino D, et al. Nanoparticulate devices for brain drug delivery. Med Res Rev. 2011;31:716–756.
   PubMed Web of Science ®Google Scholar
• Bozkir A, Saka OM. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. Drug Deliv. 2004;11:107–112.
   PubMed Web of Science ®Google Scholar
• Fattal E, Couvreur P, Dubernet C. ‘Smart’ delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev. 2004;56:931–946.
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Patwardhan GA, Liu YY, et al. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int J Pharm. 2010;400:251–259.
   PubMed Web of Science ®Google Scholar
• Andreozzi E, Wang P, Valenzuela A, et al. Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. Bioconjug Chem. 2013;24:1455–1467.
   PubMed Web of Science ®Google Scholar
• Marathe D, Mishra KP. Radiation-induced changes in permeability in unilamellar phospholipid liposomes. Radiat Res. 2002;157:685–692.
   PubMed Web of Science ®Google Scholar
• Naguib YW, Rodriguez BL, Li X, et al. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 2014;11:1239–1249.
   PubMed Web of Science ®Google Scholar
• Thatipamula RP, Palem CR, Gannu R, et al. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. DARU. 2011;19:23–32.
   PubMed Web of Science ®Google Scholar
• Vazquez-Blomquist D, Fernandez JR, Miranda J, et al. Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG. Mol Biol Rep. 2012;39:11167–11175.
   PubMed Web of Science ®Google Scholar
• Lu N, Liu Q, Li R, et al. Superior antimetastatic effect of pemetrexed-loaded gelatinase-responsive nanoparticles in a mouse metastasis model. Anticancer Drugs. 2012;23:1078–1088.
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Custodia C, et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J Control Release. 2015;207:31–39.
   PubMed Web of Science ®Google Scholar
• Corsten MF, Miranda R, Kasmieh R, et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell-derivated S-TRAIL in human gliomas. Cancer Res. 2007;67:8994–9000.
   PubMed Web of Science ®Google Scholar